One phase I/II clinical trial is recruiting patients with advanced solid tumors (including MM) and lymphomas, and they receive monotherapy treatment with CPI-0209, an EZH2 inhibitor (NCT04104776). This evidence concerns the gene EZH2 and Miyoshi myopathy.